Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interferon alpha; Interleukin-2
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms GOIRC; POLAR01
- 10 Jul 2013 Biomarkers information updated
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2007 New trial record.